BioPharma Credit PLC (BOPCF) Comparison with companies in other sectors?

BioPharma Credit PLC has a share price of 1.13B. You can analyze BioPharma Credit PLC (BOPCF) competitors across different market sectors through stock heatmaps.

What are BOPCF's NET and operating margins?

BioPharma Credit PLC (BOPCF) operating margin is around 0.80, and net profit margin is approximately 0.80 as of the latest reports.

In what way does BOPCF's earnings per share (EPS) trend reflect its financial momentum?

BioPharma Credit PLC (BOPCF) EPS is 0.06 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for BioPharma Credit PLC is 13.71, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for BioPharma Credit PLC?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for BioPharma Credit PLC like P/E which is 9.96, P/B which is 0.92, and PEG which is 2.11. Compare them with sector averages to evaluate if the stock is priced fairly.

BioPharma Credit PLC

BOPCF•PNK

Financial Services

Asset Management

$0.85

$0.85(1875713046797837.00%)

BioPharma Credit PLC (BOPCF) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.06

P/E Ratio

13.71

ROE

0.09%

Net Margin

0.80%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$959.93M

Shares OutstandingTotal number of shares issued

$1.13B

Book Value/ShareNet worth per share

$0.95

Revenue/ShareAnnual revenue per share

$0.11

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.062

Net MarginNet income as percentage of revenue

80.20%

Operating MarginOperating income as percentage of revenue

80.27%

ROEReturn on shareholders' equity

9.08%

ROAReturn on total assets

9.12%

ROCEReturn on capital employed

9.12%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.11

Cash/ShareCash and equivalents per share

$0.005

FCF YieldFree cash flow as percentage of market cap

14.23%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.10

Dividend YieldAnnual dividend as percentage of stock price

11.65%

Financial Ratios Analysis data is not available for BOPCFFinancial Ratios Analysis details for BOPCF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BOPCFSector Benchmarking details for BOPCF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for BioPharma Credit PLC Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of BioPharma Credit PLC. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account BioPharma Credit PLC's unique business strengths and challenges.

Key Financial Metrics for BioPharma Credit PLC

For BioPharma Credit PLC, essential financial indicators include EPS 0.06, PE 13.71, and ROE 0.09. These key ratios reveal insights into BioPharma Credit PLC's profitability, valuation, and operational health. Understanding these metrics enables you to compare BioPharma Credit PLC with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of BioPharma Credit PLC

Metrics like Net Margin 80.20% and ROA 9.12% shed light on how well BioPharma Credit PLC is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether BioPharma Credit PLC can sustain its operations and continue growing in the future.

Valuation and Market Position of BioPharma Credit PLC

Using ratios such as P/B Ratio 0.92 and PEG Ratio 2.11, investors can assess whether BioPharma Credit PLC is appropriately valued based on its financials and growth potential. These figures, combined with BioPharma Credit PLC's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for BioPharma Credit PLC

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $0.11, provide a snapshot of BioPharma Credit PLC's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like BioPharma Credit PLC, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for BioPharma Credit PLC

Investing in BioPharma Credit PLC based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at BioPharma Credit PLC focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;